RT Journal Article
SR Electronic
T1 New antibiotics for Gram-negative pneumonia
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 220119
DO 10.1183/16000617.0119-2022
VO 31
IS 166
A1 Bassetti, Matteo
A1 Magnè, Federica
A1 Giacobbe, Daniele Roberto
A1 Bini, Lorenzo
A1 Vena, Antonio
YR 2022
UL https://publications.ersnet.org//content/31/166/220119.abstract
AB Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by in vitro susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially Klebsiella pneumoniae carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline.Thanks to new antibiotics, there is hope in the future regarding treatment of pneumonia caused by Gram-negative bacilli. https://bit.ly/3sl2sVw